Go Search

For many women past menopause, regular screenings for invasive breast cancer (such as mammograms) and osteoporosis remind them how important it is to maintain a healthy lifestyle. In addition to what you’re already doing to protect your bones, there are lifestyle changes you can make that can help you reduce the risk of invasive breast cancer.

Acquire Healthy Habits
Exercise Most Days of the Week
Learn More with Online Resources

Acquire Healthy Habits

Maintain a Healthy Diet
Maintaining a healthy diet past menopause is an important part of a healthy lifestyle. Here are things you can do to acquire a healthy diet:

  • Use portion control to help achieve and maintain a healthy weight
  • Consume at least 5 servings of fruits and vegetables daily
  • Eat whole grains instead of processed (refined) grains
  • Reduce your intake of processed and red meats

Take Supplements that Your Doctor Recommends
If you are treating or preventing osteoporosis, your doctor may recommend that you take supplemental calcium and/or Vitamin D.

Quit Smoking
Smoking is detrimental to your overall health. If you smoke and have thought about quitting, now is the time to take charge.

Reduce Alcohol Consumption
Research has shown that more than 2 alcoholic beverages each day may increase certain health risks in women past menopause. Talk with your healthcare professional to better understand the health risks related to alcohol consumption.

Back to Top

Exercise Most Days of the Week
Aim to incorporate at least 30 minutes of moderate to vigorous exercise into your day at least 5 times a week. Exercising for longer periods of time, between 45 to 60 minutes, is preferred.

Before beginning a new exercise program, you should consult with your doctor.

Back to Top

Learn More with Online Resources
To learn more tips for staying healthy past menopause, visit the following sources:

About Invasive Breast Cancer

American Cancer Society
800-ACS-2345 (800-881-2345)
http://www.cancer.org

Cancer Research and Prevention Foundation
800-227-2732
http://www.preventcancer.org

National Breast Cancer Coalition
800-622-2838
http://www.stopbreastcancer.org

National Cancer Institute (NCI)
800-4CANCER (800-422-6237)
http://www.cancer.gov

The Susan G. Komen Breast Cancer Foundation
800-I'M AWARE (800-462-9273)
http://www.komen.org/bci

Breast Cancer Network of Strength (formerly known as Y-ME National Breast Cancer Organization)
213-986-8338
http://www.networkofstrength.org

About Osteoporosis

National Institutes of Health, Osteoporosis and Related Bone Diseases—National Resource Center
800-624-BONE or 202-223-0344
http://www.osteo.org

National Osteoporosis Foundation (NOF)
800-231-4222 or 202-223-2226
http://www.nof.org

International Osteoporosis Foundation (IOF)
(International Call) 011 41 22 994 0100
http://www.osteofound.org

U.S. Surgeon General's Report on Bone Health and Osteoporosis
http://www.surgeongeneral.gov/library/bonehealth

Back to Top

Indication for EVISTA® (raloxifene HCI tablets)
EVISTA is indicated for the treatment of osteoporosis and for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.

If you already have or have had breast cancer, EVISTA does not treat it or prevent its return, and it does not reduce the risk of all forms of breast cancer.

Indication for EVISTA® (raloxifene HCI tablets)
EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

Indication for EVISTA® (raloxifene HCI tablets)
EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

If you already have or have had breast cancer, EVISTA does not treat it or prevent its return, and it does not reduce the risk of all forms of breast cancer.

Indications for EVISTA® (raloxifene HCI tablets)
EVISTA is indicated for:

  • The treatment and prevention of osteoporosis in postmenopausal women
  • The reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis
  • The reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer

If you already have or have had breast cancer, EVISTA does not treat it or prevent its return, and it does not reduce the risk of all forms of breast cancer.

Important Safety Information About EVISTA

You should not take EVISTA if you have had or are at risk for getting blood clots in the legs, lungs or eyes, as it may increase the risk of blood clots. Stop taking EVISTA and call your doctor if you have leg pain or warmth, swelling of the legs, hands or feet, chest pain, shortness of breath or a sudden vision change, as these may be signs of a blood clot. Being unable to move around for long periods may increase this risk. If you will need to be still for a long time, talk to your doctor about ways to reduce the risk of blood clots.

EVISTA does not increase the risk of a heart attack or stroke in women who have had or are at risk for a heart attack; however; EVISTA increases the likelihood of dying from stroke in these women, should one occur. Before taking EVISTA tell your doctor if you have had a stroke, a mini-stroke, irregular heartbeat, high blood pressure, heart attack, history of smoking, or believe you have other risk factors for stroke or a heart attack.

Before Taking EVISTA

EVISTA is not right for everyone. You should only take prescription EVISTA if you are past menopause. Before taking EVISTA, talk to your doctor about all your medical conditions. If you are pregnant, nursing or may become pregnant, do not take EVISTA, as it may cause fetal harm. Women with liver or kidney disease should use EVISTA with caution. EVISTA should not be taken with estrogens in the form of pills, patches or injections.

Side Effects

Side effects may include hot flashes, leg cramps, swelling, flu-like symptoms, joint pain, and sweating. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more safety information, please see the Medication Guide and full Prescribing Information.